ADDI's Editorial Take

What is it and what does it include? 

This phase III trial included 331 participants aged 51 and older with mild to moderate AD and evaluated the long-term safety and tolerability of RSG XR (Rosiglitazone (Extended Release)), a type 2 diabetes treatment. The study also aimed to explore further the long-term efficacy of RSG XR in terms of cognitive function and overall clinical response as a function of apolipoprotein E (APOE) e4 allele status. 

How can I use this dataset to advance my research? 

This dataset is ideal if: 

  • you’re studying PPAR-γ agonists efficacy for the improvement of cognitive function in human models. 

Has this dataset helped researchers understand Alzheimer’s and other dementias better? 

Of course!  

  • AD & Pharmacokinetics:  

In 2011, researchers found no evidence of statistically or clinically significant efficacy in cognition or global function for 2 mg or 8 mg RSG XR as adjunctive therapy to ongoing AChEIs (Acetylcholine esterase inhibitors) therapy. There was no evidence of an interaction between treatment and APOE status. Safety and tolerability of RSG XR was consistent with the known profile of rosiglitazone. April 2011 – DOI:  10.2174/156720511796391935 

  • AD & Predictive biomarkers: 

In 2021, researchers found a pre-defined 6-protein predictive biomarker (IL6, IL10, CRP, TNFα, FABP-3, and PPY) that correctly classified treatment response with 100% accuracy in identifying those patients most likely to experience positive treatment response. This study provides additional proof-of-concept that a predictive biomarker can be utilized to help with screening and predicting treatment response, which holds tremendous benefit for clinical trials. March 2021 – DOI: 10.3233/JAD-201610